NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
Agency: National Institutes of Health
Assistance Listings
- 93.839 -- Blood Diseases and Resources Research
- 93.837 -- Cardiovascular Diseases Research
- 93.350 -- National Center for Advancing Translational Sciences
- 93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- 93.233 -- National Center on Sleep Disorders Research
- 93.838 -- Lung Diseases Research
Archived opportunityLast Updated: May 13, 2026
View version history on Grants.gov
Description
The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial...
markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations.
Eligibility
Eligible applicants
Business
- Small businesses
Additional information
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Grantor contact information
Description
NIH OER Webmaster
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Documents
| File name | Description | Last updated |
|---|---|---|
| RFA-HL-23-008-Full-Announcement.html | RFA-HL-23-008 Full Announcement Text | Jan 24, 2022 03:56 PM UTC |
Link to additional information
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-008.html
Archived: April 4, 2024
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
RFA-HL-23-008
Cost sharing or matching requirement:
No
Funding instrument type:
Grant
Opportunity Category:
Discretionary
Opportunity Category Explanation:
--
Category of Funding Activity:
Health
Category Explanation:
--
History
Version:
1
Posted date:
November 16, 2021
Archive date:
April 4, 2024
